Abstract
In recent years, due to the increase in the number of patients with inflammatory bowel disease (IBD) and the prolonged duration of the disease, countermeasures against IBD-associated intestinal cancer have become increasingly important. The frequency of ulcerative colitis-associated colorectal cancer (UCAC) is significantly higher than that of the general population [1], and surveillance colonoscopy is recommended for early detection [2–4]. It has been reported to contribute to the reduction of colorectal cancer incidence and mortality [5]. However, early detection of UCAC is often difficult because the boundary between the tumor and the surrounding mucosa is unclear due to modification by chronic inflammation, and because the tumor develops in a bottom-up fashion from the deep glands to the middle layer of the glandular duct, resulting in little change in the mucosal alterations.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10:639–45.
Cairns SR, Scholefield JH, Dunlop MG, et al. Guidelines for colorectal cancers screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59:666–89.
Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis: part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649–70.
Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384–413.
Bye WA, Ma C, Nguyen TM, et al. Strategies for detecting colorectal cancer in patients with inflammatory bowel disease: a Cochrane systematic review and meta-analysis. Am J Gastroenterol. 2018;113:1801–9.
Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumor development. N Engl J Med. 1988;319:525–32.
Spratt JS Jr, Ackerman LV. Small primary adenocarcinomas of the colon and rectum. JAMA. 1962;179:337–46.
Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138:2088–100.
Hussain SP, Amstad P, Raja K, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic. Cancer Res. 2000;60:3333–7.
Brentnall TA, Crispin DA, Rabinovitch PS, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994;107:369–78.
Maia L, Dinis J, Bravo M, et al. Who takes the lead in the development of ulcerative colitis-associated colorectal cancers: mutator, suppressor, or methylator pathway? Cancer Genet Cytogenet. 2005;162:68–73.
Burmer GC, Levine DS, Kulander BG, et al. c-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma. Gastroenterology. 1990;99:416–20.
Chiba T, Marusawa H, Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology. 2012;143:550–63.
Fujii S, Tominaga K, Kitajima K, et al. Methylation of the oestrogen receptor gene in non-neoplastic epithelium as a marker of colorectal neoplasia risk in longstanding and extensive ulcerative colitis. Gut. 2005;54:1287–92.
Toiyama Y, Okugawa Y, Tanaka K, et al. A panel of methylated microRNA biomarkers for identifying high-risk patients with ulcerative colitis-associated colorectal cancer. Gastroenterology. 2017;153:1634–46.
Watari J, Saitoh Y, Obara T, et al. Natural history of colorectal nonpolypoid adenomas: a prospective colonoscopic study and relation with cell. Am J Gastroenterol. 2002;97:2109–15.
Hisabe T, Tsuda S, Matsui T, Iwashita A. Natural history of small colorectal protuberant adenomas. Dig Endosc. 2010;22(Suppl 1):43–6.
Hisabe T, Hirai F, Matsui T. Development and progression of colorectal cancer based on follow-up analysis. Dig Endosc. 2014;26(Suppl 2):73–7.
Yamasaki K, Matsui T, Hisabe T, et al. Retrospective analysis of the growth speed of 54 lesions of colitis-associated colorectal neoplasia. Anticancer Res. 2016;36:3731–40.
Hisabe T, Matsui T, Yamasaki K, et al. Possible earlier diagnosis of ulcerative colitis-associated neoplasia: a retrospective analysis of interval cases during surveillance. J Clin Med. 2021;10:1927.
Wang YR, Cangemi JR, Loftus E, et al. Rate of early/missed colorectal cancers after colonoscopy in older patients with or without inflammatory bowel disease in the United States. Am J Gastroenterol. 2013;108:444–9.
Rutter M, Saunders B, Wilkinson K, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130:1030–8.
Bessissow T, Dulai PS, Restellini S, et al. Comparison of endoscopic dysplasia detection techniques in patients with ulcerative colitis: a systematic review and network meta-analysis. Inflamm Bowel Dis. 2018;24:2518–26.
Feuerstein JD, Rakowsky S, Sattler L, et al. Meta-analysis of dye-based chromoendoscopy compared with standard- and high-definition white light endoscopy in patients with inflammatory bowel disease at increased risk of colon cancer. Gastrointest Endosc. 2019;90:186–95.
Watanabe T, Ajioka Y, Mitsuyama K, et al. Comparison of targeted vs random biopsies for surveillance of ulcerative colitis-associated colorectal. Gastroenterology. 2016;151:1122–30.
Moussata D, Allez M, Cazala-Hatem D, et al. Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy? Gut. 2018;67:616–24.
Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk patients with Crohn’s disease. Aliment Pharmacol Ther. 2006;23:1097–104.
Yano Y, Matsui T, Uno H, et al. Risks and clinical features of colorectal cancer complicating Crohn’s disease in Japanese patients. Gastroenterol Hepatol. 2008;23:1683–8.
Higashi D, Katsuno H, Takahashi K, et al. Current state of and problems related to cancer of the intestine tract associated with Crohn’s. Anticancer Res. 2016;36:3761–6.
Hirano Y, Futami K, Higashi D, et al. Anorectal cancer surveillance in Crohn’s disease. J Anus Rectum Colon. 2018;2:145–54.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Hisabe, T. (2022). Development and Course of Inflammatory Bowel Disease-Associated Intestinal Cancer. In: Matsui, T., Iwashita, A., Matsumoto, T., Hisabe, T., Futami, K., Tanabe, H. (eds) Atlas of Inflammatory Bowel Disease-Associated Intestinal Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-19-3413-1_5
Download citation
DOI: https://doi.org/10.1007/978-981-19-3413-1_5
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-3412-4
Online ISBN: 978-981-19-3413-1
eBook Packages: MedicineMedicine (R0)